Loading...
ALNOV logo

Novacyt S.A.ENXTPA:ALNOV Stock Report

Market Cap €39.9m
Share Price
n/a
1Y4.9%
7D18.3%
1D-6.7%
Portfolio Value
​
View

Novacyt S.A.

ENXTPA:ALNOV Stock Report

Market Cap: €39.9m

Novacyt (ALNOV) Stock Overview

Develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. More details

ALNOV fundamental analysis
Snowflake Score
Valuation3/6
Future Growth1/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Rewards

Revenue is forecast to grow 19.74% per year

Trading at good value compared to peers and industry

Risk Analysis

Earnings have declined by 68.7% per year over past 5 years

Highly volatile share price over the past 3 months compared to the French market

Does not have a meaningful market cap (€40M)


ALNOV Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW470,065 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
470,065 investors already sharing narratives
View all narratives

Novacyt S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Novacyt
Historical stock prices
Current Share Price€0.51
52 Week High€1.04
52 Week Low€0.29
Beta1.11
1 Month Change22.82%
3 Month Change-4.46%
1 Year Change4.90%
3 Year Change-45.78%
5 Year Change-88.73%
Change since IPO-94.09%

Recent News & Updates

Recent updates

Analysis Article • Jan 27

Companies Like Novacyt (EPA:ALNOV) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Aug 14

We're Not Very Worried About Novacyt's (EPA:ALNOV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Analysis Article • May 27

Novacyt S.A. (EPA:ALNOV) Held Back By Insufficient Growth Even After Shares Climb 55%

Novacyt S.A. ( EPA:ALNOV ) shareholders would be excited to see that the share price has had a great month, posting a...
Analysis Article • Jan 09

There's No Escaping Novacyt S.A.'s (EPA:ALNOV) Muted Revenues

With a price-to-sales (or "P/S") ratio of 2.3x Novacyt S.A. ( EPA:ALNOV ) may be sending bullish signals at the moment...
Analysis Article • Sep 30

Novacyt S.A. (EPA:ALNOV) Not Doing Enough For Some Investors As Its Shares Slump 36%

The Novacyt S.A. ( EPA:ALNOV ) share price has softened a substantial 36% over the previous 30 days, handing back much...
Analysis Article • Aug 16

Novacyt S.A. (EPA:ALNOV) Stock Catapults 39% Though Its Price And Business Still Lag The Industry

Novacyt S.A. ( EPA:ALNOV ) shares have had a really impressive month, gaining 39% after a shaky period beforehand. Not...
Analysis Article • Aug 15

Here's Why Novacyt (EPA:ALNOV) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 14

Revenues Working Against Novacyt S.A.'s (EPA:ALNOV) Share Price

Novacyt S.A.'s ( EPA:ALNOV ) price-to-sales (or "P/S") ratio of 3.1x might make it look like a strong buy right now...
Analysis Article • Nov 28

Is Novacyt (EPA:ALNOV) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Jul 04

We're Keeping An Eye On Novacyt's (EPA:ALNOV) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Jan 24

Estimating The Fair Value Of Novacyt S.A. (EPA:ALNOV)

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Novacyt S.A...
Analysis Article • Mar 18

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
Analysis Article • Nov 25

With EPS Growth And More, Novacyt (EPA:ALNOV) Is Interesting

It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Analysis Article • Sep 29

Little Excitement Around Novacyt S.A.'s (EPA:ALNOV) Earnings As Shares Take 25% Pounding

Novacyt S.A. ( EPA:ALNOV ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article • Mar 08

Novacyt's (EPA:ALNOV) Wonderful 999% Share Price Increase Shows How Capitalism Can Build Wealth

Novacyt S.A. ( EPA:ALNOV ) shareholders might be concerned after seeing the share price drop 21% in the last quarter...
Analysis Article • Jan 22

Is Novacyt S.A.'s(EPA:ALNOV) Recent Stock Performance Tethered To Its Strong Fundamentals?

Most readers would already be aware that Novacyt's (EPA:ALNOV) stock increased significantly by 29% over the past...
Analysis Article • Dec 15

Calculating The Intrinsic Value Of Novacyt S.A. (EPA:ALNOV)

Does the December share price for Novacyt S.A. ( EPA:ALNOV ) reflect what it's really worth? Today, we will estimate...
Analysis Article • Nov 19

We're Not Counting On Novacyt (EPA:ALNOV) To Sustain Its Statutory Profitability

Broadly speaking, profitable businesses are less risky than unprofitable ones. However, sometimes companies receive a...

Shareholder Returns

ALNOVFR BiotechsFR Market
7D18.3%1.0%-0.03%
1Y4.9%50.0%6.1%

Return vs Industry: ALNOV underperformed the French Biotechs industry which returned 50% over the past year.

Return vs Market: ALNOV underperformed the French Market which returned 6.1% over the past year.

Price Volatility

Is ALNOV's price volatile compared to industry and market?
ALNOV volatility
ALNOV Average Weekly Movement15.2%
Biotechs Industry Average Movement7.1%
Market Average Movement4.6%
10% most volatile stocks in FR Market10.3%
10% least volatile stocks in FR Market2.3%

Stable Share Price: ALNOV's share price has been volatile over the past 3 months compared to the French market.

Volatility Over Time: ALNOV's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of French stocks.

About the Company

FoundedEmployeesCEOWebsite
2006216Lyn Reeswww.novacyt.com

Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine.

Novacyt S.A. Fundamentals Summary

How do Novacyt's earnings and revenue compare to its market cap?
ALNOV fundamental statistics
Market cap€39.95m
Earnings (TTM)-€27.43m
Revenue (TTM)€23.42m
1.6x
P/S Ratio
-1.4x
P/E Ratio

Is ALNOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALNOV income statement (TTM)
RevenueUK£20.03m
Cost of RevenueUK£8.51m
Gross ProfitUK£11.52m
Other ExpensesUK£34.97m
Earnings-UK£23.45m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.32
Gross Margin57.49%
Net Profit Margin-117.09%
Debt/Equity Ratio0%

How did ALNOV perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/13 19:52
End of Day Share Price 2026/08/13 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Novacyt S.A. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Christophe-Raphael GanetODDO BHF Corporate & Markets
Christian GlennieStifel, Equities Research